ADMA Biologics Pushes Back Against Short-Seller Allegations; Stock Down

ADMA Biologics publicly rebutted a Culper Research short-seller report, calling the document misleading and inaccurate. The company reiterated its commitment to transparent financial reporting; expect potential short-term share volatility and increased investor scrutiny, but no new financial metrics or material disclosures were provided.

Analysis

ADMA Biologics publicly rebutted a Culper Research short-seller report, calling the document misleading and inaccurate. The company reiterated its commitment to transparent financial reporting; expect potential short-term share volatility and increased investor scrutiny, but no new financial metrics or material disclosures were provided.